comparemela.com

Latest Breaking News On - Aleix prat - Page 1 : comparemela.com

MEDSIR presents the results of three new studies at ESMO 2023: LUPER, focusing on lung cancer, and two translational studies of PHERGain in breast cancer

/PRNewswire/ MEDSIR, a company specializing in the strategic design of independent clinical research, today presented the results of three new studies at.

United statesAntonio callesAntonio llombart cussacAleix pratJavier cortGregorio maraDrug administrationAmerican society of clinical oncologyEuropean society for medical oncologyEuropean societyMedical oncologyAmerican societyClinical oncologyHealth care amp hospitalsMedical pharmaceuticalsQuity amp inclusion

Oncolytics Biotech® Inc : Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclitaxel

United statesComunidad autonoma de catalunaMecklenburg vorpommernBruxelles capitaleTimothy mccarthyAleix pratThomas heinemanMartinej piccartStefan klotterJon pattonOncolytic reovirus pelareorepMatt coffeyOncolytics biotech incSecurities exchangeCompany contactAmerican society of clinical oncology

Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

Pelareorep-paclitaxel combination reduced risk of disease progression by 71% compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclitaxel vs. 13.3% with. | June 5, 2023

United statesBruxelles capitaleComunidad autonoma de catalunaOncolytic reovirus pelareorepMatt coffeyAleix pratTimothy mccarthyThomas heinemanJon pattonMartinej piccartAmerican society of clinical oncologySecurities exchangeCompany contactOncolytics biotechOncolytics biotech incClinical oncology

Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting

/PRNewswire/ Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced that it will host a key opinion leader webinar to discuss data from the randomized.

Bruxelles capitaleComunidad autonoma de catalunaUnited statesInstitut jules bordetJon pattonTimothy mccarthyWilliaml mcguireMartinej piccartDavida karnofskyAleix pratCharlesm perouEuropean society for medical oncologyOncolytics biotech incUniversity of londonCompany contactTherapeutics in solid tumors lab

Oncolytics Biotech® Inc : Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting

Key opinion leader webinar to take place on June 5, 2023 at 8:00 a.m. ET SAN DIEGO and CALGARY, AB, May 26, 2023 /PRNewswire/ Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced

United statesComunidad autonoma de catalunaBruxelles capitaleDavida karnofskyInstitut jules bordetJon pattonCharlesm perouWilliaml mcguireMartinej piccartAleix pratGewinn nurTimothy mccarthyAmerican society of clinical oncologyEuropean cancer organisationTherapeutics in solid tumors labUniversity of barcelona

vimarsana © 2020. All Rights Reserved.